For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration has approved Insmed's daily pill brensocatib, which will be sold under the brand name Brinsupri . The drug is designed to treat non-cystic fibrosis bronchiectasis, a chronic condition that damages the lungs and makes it harder to clear mucus, the company said in a statement. The approval comes after the medication succeeded in one of last year's most closely watched Phase 3